Targeted Positron Emission Tomography-Tracked Biomimetic Codelivery Synergistically Amplifies Ferroptosis and Pyroptosis for Inducing Lung Cancer Regression and Anti-PD-L1 Immunotherapy Efficacy

The chemoresistance and systemic toxicity of cisplatin (CDDP) severely limit its application in the treatment of non-small cell lung Cancer (NSCLC). Here, I-124 labeled Cancer cell membrane biomimetic nanovesicles loading Polyphyllin VI (PPVI) and CDDP (termed ¹²⁴I-P/C@CMLvs) were constructed to enhance the sensitivity and efficacy of CDDP. The radiochemical purity (RCP) of ¹²⁴I-P/C@CMLvs reached more than 99% and maintained reliable stability in vitro. Micro-positron emission tomography (micro-PET) imaging of I-124 quantitatively revealed the distribution and specific homologous tumor targeting ability of ¹²⁴I-P/C@CMLvs in vivo with superior diagnosis performance, beneficial for dynamically monitoring the efficacy against NSCLC. Loaded PPVI significantly strengthened the sensitivity of NSCLC to CDDP therapy and exerted synergistic anti-tumor effect in vitro and in vivo, which was achieved by PPVI promoting p53 deubiquitination and stimulating Reactive Oxygen Species (ROS) production to trigger the crosstalk between the amplification of GPX4 signaling-mediated Ferroptosis and NLRP3/GSDMD/Caspase-1 axis-mediated Pyroptosis. ¹²⁴I-P/C@CMLvs also significantly stimulated the infiltration of immune cells including dendritic cells, CD8⁺ T cells, and CD4⁺ T cells in tumor tissues (P < 0.05). The combination of ¹²⁴I-P/C@CMLvs and anti-PD-L1 therapy further synergistically promoted NSCLC regression. Altogether, ¹²⁴I-P/C@CMLvs provide a transformational solution to the challenge of improving CDDP sensitivity and realizing the integration of diagnosis, treatment, and monitoring of NSCLC.

ferroptosis; immunology; micro-PET imaging; non-small cell lung cancer; pyroptosis.